Skye Bioscience Inc SKYE

Healthcare Biotechnology

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

NDAQ:SKYE - Post by User

Skye Bioscience Inc > The arrest of AVTAR DHILLON

<< Previous

Bullboard Posts

Next >>

Comment by Stockqueen77on Aug 05, 2021 11:23pm

267 Views

Post# 33662025

RE:The arrest of AVTAR DHILLON

Punit Dhillon sat as a director of Arch Therapeutics...wonder if he'll be sitting beside his uncle and his mentor Avtar Dhillon, the one who taught him how to scam people.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?